new
normal medic devic
introduc bottom-up base bear case
impact assumpt continu see acut impact
rel rapid recoveri next month
recommend investor consid name posit
benefit phase recoveri
framework financi impact acut near-term
durat long impact last question base case
see revenu impact growth averag see revenu ep
return normal respect see
model chang summari whether base case assumpt lean
aggress conserv answer come week regardless
recent day clear investor start invest aggress
elect econom sensit phase recoveri stori whether
trend continu near-term hing case rate progress access person
protect equip ppe sever econom pressur liquid
issu scant recommend lean durat multipl
opportun valu creation initi focu insul posit
off-set phase stori baxter bd abbott hillrom busi
remain insul see upsid believ consid phase
recoveri stori along phase make sens area focu us
zimmer biomet growth irhythm axon si-bon
shift roadmap earli last week roadmap
provid multi-phas invest framework top-down financi impact
assess report outlin comprehens bottom-up review
financi impact recoveri examin multitud factor includ
elect emerg revenu mix revenu earn implic
pace recoveri suppli chain stabil liquid expect
acut impact occur increasingli look price
share debat shift phase recoveri fact
week phase bucket revers perform gap insul phase
see perform tracker given limit liquid
issu discuss shift phase recoveri name make sens
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
recoveri period broadli continu see acut
top-line impact averag follow modest recoveri
impact extend earli assum materi ep drop-
rel reflect access issu inventori suppli
chain pressur select corpor initi shield employe
econom impact period time also consid offset
pressur includ less travel control spend certain
area model chang summari compani specif model
chang estim impact
base case look price prior downturn
use recent market peak larg cap coverag trade
price-to-earnings premium reflect compress med-tech
rel valuat peak premium market august consid
market sell adjust number larg cap valuat remain near
prior level today premium rel consist pre-covid-
level interpret follow market price
normalci limit long-term structur impair
assign group
bear case sever factor defin scenario depth
breadth diseas progress recoveri hospit infrastructur
economi base case assumpt remain center peak case
us occur next week risk magnitud
durat high case rate region new york new jersey washington
michigan california cours could chang acut recoveri
hospit infrastructur happen month china see recent china
perspect note highli depend diseas progress social
distanc initi access critic suppli magnitud spread
factor weigh hospit inpati outpati recoveri
devic remain rel insul econom pressur fulli
immun correl certain devic segment would impact
recoveri orthoped ophthalmolog bear case see model
chang see sever acut revenu hit
versu base case labor recoveri
month togeth drive averag revenu lower
higher drop impact versu base case
liquid issu manag broadli forese materi liquid issu
affect coverag even stress test revenu ep
coven could potenti breach
perhap zimmer biomet reflect headlin risk
address amend waiver bank syndic mani
smid cap recent rais capit ok mani like pare
burn rate could impair commerci develop near-term
detail review liquid chang see exhibit
chang reflect signific number revis updat market
multipl methodolog remain rel consist conjunct
see outlier
underweight equal-weight elect mix modest capit
exposur clear adjust ebitda risk appear
reflect diagnost test could provid modest off-set
intermediate-term assum upgrad
ew price target
equal-weight underweight mr-linac placement
pressur near-term hospit center shift prioriti away
larg scale capit purchas despit recent capit rais dont see
path profit see liquid linger concern
compani achiev scale downgrad uw price target
prior mse ep
prior mse ep
number base calendar year
prior mse ep
prior mse ep
number base calendar year
prior mse ep
prior mse ep
number base calendar year
premium larg cap
premium larg cap
discount smid
premium larg cap
premium smid
discount smid
msd discount
premium larg cap
premium larg cap
discount larg cap
discount larg cap
line larg cap
line diabet larg cap
discount dentspli
premium smid
discount larg cap
in-lin smid
discount larg cap
discount smid
discount smid
exhibit summari price target chang
premium larg cap
in-lin larg cap
discount hg smid
premium larg cap
premium smid
discount smid
msd discount
premium larg cap
premium larg cap
discount larg cap
discount larg cap
discount larg cap
premium hg smid
discount smid
premium smid
discount larg cap
premium hg smid
discount larg cap
discount smid
line hg smid
discount smid
coven set step total debt adj
ebitda year-end impli ebitda
leeway rel boston leverag coven set
impli potenti breach follow
ebitda shortfal
like tight headroom coven
 revis outlook stabl neg
 revis stabl neg
 revis stabl neg
debt
debt
equiti
equiti
equiti
equiti
convert
convert
convert
coven dynam watch
improv invest case driven top bottom line acceler
base case methodolog base multipl base case ep
premium larg cap med-tech
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
newer product launch libr
quicker expect upsid synergi
robust em end market provid
larg share gain china
new product launch mitraclip
prole medium term margin grow
abbott organ growth sustain
driven broad busi momentum
key product growth libr
abbott high exposur emerg
market consumer-direct busi
drive potenti sustain double-
digit earn growth also subject
compani em currenc exposur
highest among devic coverag
leverag opportun visibl across
nutrit diagnost epd peer
margin demonstr potenti
view descript risk reward theme
libr fail gain traction us conrm
mitraclip adopt slower
nutrit end market take longer
recov abbott invest grow revenu
offset margin improv em
organ growth acceler driven devic
product launch diabet ep
continu oper margin expans core
abbott combin cost synergi execut
st jude aler
china india
view explan region hierarchi
research highest favor quintil
libr mitraclip alin grow faster
headwind strengthen us dollar
failur libr mitraclip alin drive
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
abiom slowdown structur transient
price target support dcf assum wacc
termin growth impli multipl base case sale repres
discount high growth devic peer assum sale grow driven
continu impella penetr protect pci shock
growth slow seen prior
year teen y/i growth impella growth
slowdown becom structur
margin expans pace slow stand
origin lrp
reimburs could head lower
stemi pivot trial continu
repres key longer term tam
expans opportun market
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
impella penetr take faster
expect util increas exist
impella site driven new product
launch incres data expans
effort organ growth sustain
longer tail stemi
opportun posit feasibl day
multipl expand higher growth
durabl longer
dcf analysi equat
impact less pronounc
expans opportun posit
reach ebit margin
multipl high growth peer
lack competit peer
protabl balanc transit
matur adopt curv
consensu
view descript risk reward theme
recoveri prolong mid
anomal impella sale growth
deceler doubl digit multipl
contract reect slower growth prole
potenti market size disappoint and/or
expans delay
sustain reimburs broader drg
pma approv rp launch ecp
broader commerci launch japan
us stemi impli
view explan region hierarchi
research highest favor quintil
faster expect impella roll-out
revers trend prior year propos
faster expect stemi expans
neg headlin impact
impact meaning
emerg competit ahead expect
market present attract opportun
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
product launch drive top-line acceler upper-ti ep growth prole
pt repres base case ep estim discount back year in-lin
alcon formerli divis novarti
ophthalmolog
expect alcon pipelin sale
capital-expenditure reinvest drive inect
top-line revenu growth margin
expans post spin revers
share loss iol intraocular lens
contact lens leverag
reinvest drive margin
see upper teen ep growth prole
emerg time alcon place
upper tier larg cap med-tech
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
initi balanc sheet deploy
drive return materi lrp
top-line compound-annual-growth-rate
oper margin alcon
valuat top end
compani alcon abl revers share
loss iol contact lens leverag
reinvest drive margin deploy
exibl balanc sheet lead upper
tier med-tech return prole time
execut miss panoptix
fail catalyz top-line growth margin
disappoint compani reinvest drive
growth growth fall lower end
lrp rang margin stay
low lead lower valuat
panoptix primari driver implant
acceler drive bp y/i corpor
growth gm accret
primari driver contact
len acceler drive bp y/i
corpor growth
china india
view explan region hierarchi
panoptix gain greater traction
anticip
panoptix gain lower
competit particularli contact lens
lower cost on-line provid
margin expans take longer materi
certain hedg fund exposur held mspb
inform may inconsist may reect
exposur short exposur sector total net
short exposur across sector long exposur
busi pressur continu
deriv base case scenario price target reect ev
ebitda multipl discount smid med-tech coverag
market reward avano accret
deal on-q recoveri avano execut
larg acquisit drive growth
earn accret growth
restructur plan progress accord
plan covid resili greater
transform proce estim
high avano moder impact
covid path toward oper
transform price
believ investor alreadi price
major benet post- ip cost
transform risk near-term
revenu headwind make upsid mid-
headwind within
challeng chronic expect
resolv earli
materi upsid requir view
limit visibl time
covid like impact
consensu
view descript risk reward theme
restructur prove challeng
medic devic sale growth low/mid
singl digit restructur initi
yield expect benet lead lower
earn level covid impact greater
deploy half deal capac could drive
ebitda accret ep
growth on-q drive pt corpor
china india
view explan region hierarchi
signic near-term recoveri on-q pain
avano execut larg accret
pain manag resili covid
on-q stabil anticip
coolief reimburs privat payor
less resili covid expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
disrupt sacral neuromodul snm market
price target base sale discount high growth smid cap
peer support dcf
axon pois materi disrupt
market histor
domin given superior
r-snm product substanti smaller
size longer life recharg
natur vs current market lead devic
think axon take materi share
ahead competit respons expect
next-gen product compar
superior axon devic
better innov snm acceler
market growth mid-singl digit
mid-teen
view descript risk reward theme
expect reach
drive market acceler benet
take share grow market axon
launch differenti product
acceler snm market growth
launch fail ramp expect
competit hit market sooner
expect materi lower price
axon market share top teen
view explan region hierarchi
axon take share anticip
snm market acceler mse
current physician relationship could
sticki imagin make difcult
next-gener competit respons
market appetit high-growth pre-
impact multipl regardless
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt reect multipl base case ebitda repres
discount larg cap peer set primarili given risk lrp miss compani
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
baxter current multipl reect
wamgr potenti
acceler medic deliveri
nutrit dynam stabil pipelin
baxter premium balanc sheet asset
risk low-return capit deploy
overst expect disciplin
approach involv repurchas
medic deliveri nutrit
headwind stabil
contribut low mid-singl digit growth
come year
growth leverag opportun
allow baxter reach low-doubl digit
earn growth level
includ acceler
view descript risk reward theme
baxter margin ramp faster anticip
assum compound-annual-growth-rate back
new product initi margin hit
higher expect guidanc
om/gm ratio
capit wacc return
diversifi faster growth end market
drive higher demand
deliveri nutrit product baxter
achiev organ sale growth
new product geograph expans
drive acceler margin continu
expand baxter execut tuck-in
medium size deal also buy back
baxter new product initi fail
deliv growth slow compound-annual-growth-rate
benet product mix fail materi
margin expans slow materi
result oper margin
strateg action fail occur
deliv wacc return
medic deliveri upsid drive
baxter expect new product sale
drive pt compound-annual-growth-rate
deploy balanc sheet
bp margin expans drive pt
china india
view explan region hierarchi
research highest favor quintil
crrt benet
acceler meaning
renal growth ahead expect driven
aakhi theranova
margin expans estim
disrupt surgeri nutrit
materi expect
potenti activ below- wacc
inabl gener oper leverag
inabl grow wamgr
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
path less clear rel resili
price target base multipl base case
ebitda one turn larg cap peer set organ growth sustain continu
new product ramp partial off-set china pump nois prior
stabil cost program gain traction bard synergi integr track
sustain growth prole
potenti double-digit earn growth
head last year deal
model bard remain meaning driver
margin improv lever growth
acceler support em penetr
aggress action cost may
expect rel resili covid
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
resili covid exce expect
sale acceler bard drive
addit growth high singl digit
bd deliv synergi materi
forecast ahead schedul
manufactur reloc erp
implement yield greater expect
organ growth sustain becom
evid new product ramp
integr track bd/bard
covid impact greater expect bard
integr take longer anticip
organ growth slow due
addit eu auster poor pipelin
buyback poor execut cost
initi addit price pressur
multipl contract low end
em repres around sale may
drive growth acceler
protabl doubl digit growth like
requir exceed guidanc
china india
view explan region hierarchi
research highest favor quintil
swift fda resolut result minim
impact result
faster expect btk approv
synergi realiz greater ahead
integr lag promis synergi fail
prolong fda process resolut
competit pressur em mount
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
peer top bottom line growth drive posit risk-reward
price target base multipl base case ep
assum trade premium larg cap peer justi superior emerg
growth margin expans opportun leverag prole
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
matur pipelin augment
drive sustain hsd organ growth
prole bp annual margin
expans drive mid teen ep growth
support premium valuat peer
organ revenu growth
sustain boston shift
faster end market share gain
continu wamgr shift today
margin expans driven
integr oper efcienc
balanc sheet exibl improv
view descript risk reward theme
impact mute organ
growth acceler doubl digiti
pipelin program outperform
sale inect faster expect high
increment protabl new growth
driver better leverag recent
acceler margin expans drive
high teen greater ep growth
impact prove pronounc
elect durabl procedur
follow acut recoveri
sustain execut support
growth stori recent build
pipelin program drive above-p
compound-annual-growth-rate oper margin remain track
bp annual improv
next sever year drive mid-teen ep
pressur multipl front
less accret organ growth key
pipelin product fail come market
tavr fail gain traction stent
price share pressur increas
weigh organ growth requir
pipelin focus expand
higher growth end market wamgr move
long term margin expans target
beyond suggest plenti room
china india
view explan region hierarchi
research highest favor quintil
less meaning expect
product ramp faster expect
share gain pronounc
achiev lotu expans
increas competit core de
market competit product launch
failur execut plan pipelin
program integr
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
price target reect ev sale multipl premium high
continu glucos monitor cgm
expos signic secular growth
expand type
type diabet us alon see
long runway cgm penetr grow
long term driven
product evolut improv form
factor integr insulin dose
accuraci eas use pharmaci
technolog leadership
sustain full launch
competit present price risk
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
guardian libr traction limit
prove market expans premium price
sustain libr seen inferior
product success non-intens
pbm distribut drive clear path
om
revenu growth sustain
pressur price pressur larg
off-set volum shift
pharmaci integr system
type adopt rate
lower share price pressur limit
protabl guardian libr becom
competit core medicar
user libr disrupt price model
sensor price collaps cgm fail gain
traction non-intens popul
delay unabl drive gm expans
new patient larg pharmaci
channel sustain us growth europ
sustain technolog
leadership form factor/ integr
advantag competitor
china india
view explan region hierarchi
research highest favor quintil
libr delay beyond
launch ahead expect late
price headwind less anticip
guardian libr competit greater
expect limit new patient start
limit path protabl
delay failur pipelin catalyst
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
tavr market expans continu low risk mitral catalyst
dcf-base analysi reect tavr market reach global
see gradual expans low risk popul follow low-risk data
complement growth rate higher risk us eu popul ew share declin
time remain market leader
long-term potenti market expans
lower risk remain underappreci
drive out-performance time
see market expans billion
penetr durabl reect
continu see tavr drive
long-term ebit margin high
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reect uncertainti futur
market
view descript risk reward theme
risk prove bridg far valv
durabl remain outstand issu
younger patient still tavr market
grow billion limit low
risk intermedi risk traction sapien
share slip traction
acceler competit boston
off-set continu product
materi slower peer
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
share tavr market grow
bn tavr increasingli becom
therapi choic even low risk
patient drive penetr
expect price declin
lower expect rate
base case ep support
time tavr market reach
global see gradual
expans low risk popul
follow low-risk data
complement growth rate higher risk
us eu popul ew share declin
time remain market
leader coapt result mitral path
forward key edward trial timelin
launch need addit clariti oper
leverag acceler long-term margin
penetr tavr lower risk popul
critic near term medium term
increas visibl structur heart
portfolio key durabl long term growth
china india
view explan region hierarchi
research highest favor quintil
expect
expect
robust commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
us european reimburs pressur
price time
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
price target base base case ebitda estim turn
discount smid peer see justi given structur lower growth margin
prole howev envista maintain yield vs peer see key
envista lead manufactur dental
implant comprehens portfolio
equip consum
compani move past acut
industri disrupt past year
launch sever new product
drive revenu acceler
margin expans initi could
meaning driven improv product mix
cost save program
view descript risk reward theme
recoveri occur rapidli dental
discretionari procedur spark
uptak robust growth acceler
structur result
favor mix combin cost
initi drive bp margin annual
impact sever dental
orthodont procedur recoveri
begin late envista
anniversari channel disrupt
segment ration effort
pressur implant growth spark
contribut growth margin
disrupt persist
recoveri longer anticip
distributor realign ensu volatil
channel new product uptak
mute competit pressur rise
dso preval drive materi price
headwind pt per year save
program fail drive meaning margin
pt market share clear align
market drive pt organ growth
pt market share fully-tap implant
market drive bp organ growth
bp margin expans drive pt ep
china india
view explan region hierarchi
research highest favor quintil
recoveri signic dental
growth faster anticip
mix cost save program drive margin
delay dental procedur
price pressur result dso preval
mute new product uptak implant
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
deriv base case scenario price target base ebitda
smid cap devic peer see warrant given outsiz organ growth
prole howev slightli off-set limit leverag opportun
globu demonstr abil
maintain innov lead core spine
diversifi lead
multipl avenu growth includ
recon imag
robot placement continu drive
sentiment see ampl runway
multipl system market
 leverag mute
given heighten invest howev
expect modestli revers
lead attract invest
view descript risk reward theme
recoveri faster expect
pent-up demand robot drive
upsid trauma ramp faster
anticip becom meaning
driver growth intern
organ growth prole shift becom dd
impact like signic
follow recoveri capit
placement like mute
limit leverag ep growth
like persist intermedi term
expans opportun recon
impact sever
drag spine market becom
challeng price pressur
increas competit challeng robot
persist greater extent excelsiusgp
placement fail acceler trauma
contribut remain limit
invest continu weigh
bp organ growth
trauma bp market penetr impli
bp organ growth
growth
pt growth upsid drive bp ep
china india
view explan region hierarchi
research highest favor quintil
recoveri faster anticip
recon robot system prove
creat mute robot placement
competit dynam robot intensifi
heighten invest continu pressur
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
price target reect ebitda discount back one year
ve-turn premium smid cap peer given superior organ growth prole materi
plasma collect volum unaffect
upsid nexsi price cost
save drop balanc sheet
achiev per liter increment
plasma price nexsi greater cost
save drop balanc sheet
deploy drive materi upsid
beyond
abl
nexsi achiev two larg
custom contract save
provid durabl margin leverag
stori tie long-
rang plan lrp doubl oper
incom quadrupl
turnaround primarili lever nexsi
compani next-gener plasma
nexsi valu creation materi withth
yield opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect
share prot increment per
liter price indic nexsi alon
drive lrp object
drive materi inect
view descript risk reward theme
growth next nexsi
unabl gain materi price benet
nexsi unabl creat materi valu
custom and/or unabl
program unabl achiev materi
drop-through initi expect due
nexsi drive increment valu per
liter plasma custom haemonet
expect particip prot share
oper excel program
drive bp margin year
china india
view explan region hierarchi
research highest favor quintil
larg custom contract come earlier
consensu anticip
save program continu drive
impact plasma donat
larg custom declin convert nexsi
save program fail materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
discount narrow hillrom drive durabl msd growth
price target reect ev/ebitda multipl ebitda discount
annual growth margin expans
surpass lrp driven revenu upsid
mix cost initi manag
remain focus addit deal shift
wamgr higher
organ growth rate msd
beyond compani execut
recognit growth stabil visibl
margin improv drive multipl
hill-rom multipl re-rat
growth move higher volatil
decreas hillrom revenu base
diversi digit new product
launch em penetr drive
hill-rom growth rate durabl
lrp achiev hillrom new
lrp call growth
annual om expans
ep compound-annual-growth-rate see new lrp
achiev given product pipelin
remain robust end market mix
digit improv lift margin
healthi hospit budget risk
consider elect year
consensu
view descript risk reward theme
organ growth remain lsd slowdown
capital-expenditure environ hurt pss
pipelin fail materi expect
initi manifest plan
along top-line shortfal
drive limit margin improv
multipl fall lrp fail
pipelin product drive
increment revenu year lrp
grow strong double-digit
emerg marketspenetr em
china india
view explan region hierarchi
research highest favor quintil
plan
initi drive margin higher
pipelin traction slow fail materi
upcom product
margin leverag prove difcult
materi declin capital-expenditure environ
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
price target base ebitda multipl turn discount larg
cap devic peer see discount warrant given oper slower growth
end-market limit top-line upsid efcient structur limit ep upsid
beyond hsd/ldd growth partli driven buy-back activ
given share gain key segment breast
dx nearli tap
compani alreadi oper
efcient om/gm ratio vs peer
leverag ep growth like
deriv buyback
see increas activ
necessari shift wagmr higher
drive multipl
consensu
view descript risk reward theme
off-set procedur weak
recoveri rapid efcient
alloc capit accret shift
wamgr msd region creat
sustain runway growth
accret augment share
segment dx test provid
modest off-set activ necessari
fundament shift growth prole
higher leverag limit near-
suggest efcienc share buyback
continu drive ep growth
procedur weak prolong
dx test impact mute
deceler back region post-
share gain becom tap
breast dx ep growth mute msd
driven limit oper leverag
deploy creat dis-synergi
advers impact organ growth
digit mammographi system
market yet convert creat
ampl runway breast health growth
share repurchas buy-back activ
drive point ep growth
china india
view explan region hierarchi
research highest favor quintil
upsid mdx
deploy capit enter faster growth
breast health dx segment growth rate
acceler
dx test impact mute via
procedur delay
peer effect cap organ
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
long-term omnipod growth sustain
price target reect ev sale multipl base case
premium high growth smid cap peer
remain comfort
revenu growth omnipod continu
penetr insulin-intens diabet
popul given eas use form factor
access us pharmaci
path revenu clear
driven channel shift pharmaci
payg model ex us growth
expect horizon launch late
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ev/sal support dcf
ex us reacceler
underli growth payg model
shift pharmaci acceler us growth ap
competitor prove market expans
immateri omnipod growth greater
scale oper efcienc
pharmaci channel drive om
next year
ev/sal support dcf
us growth remain driven
shift pharmaci payg model
ex-u grow high-teen
mdi pediatr posit insul
omnipod ap competitor risk
remain path sale
gm clear like oor
horizon ap launch late
ev/sal support dcf
fail off-set competit headwind dash
 horizon adopt modest ap
timelin slip path greater protabl
becom less clear greater invest
requir support growth
shift pharmaci pay-as-you-go
distribut sustain ex us growth
path protabl improv us
horizon launch
china india
view explan region hierarchi
research highest favor quintil
ex-u growth re-acceler
greater abil drive manufactur
disclosur addit drug deliveri deal
